Resistin

Philip G. McTernan, Christine M. Kusminski, Sudhesh Kumar

Research output: Contribution to journalReview article

142 Citations (Scopus)

Abstract

Purpose of review: Resistin, a cysteine-rich 12.5 kDa polypeptide, is a recently discovered adipocytokine with a controversial history regarding its role in the pathogenesis of obesity-mediated insulin resistance and type 2 diabetes mellitus. Whilst current studies appear to re-affirm the role of resistin on glucose homeostasis in rodent systems, we are still unravelling the functionality of resistin in human biology in respect to glucose metabolism and insulin signalling. This review will summarize the current knowledge, put into context the developments to date and discuss the controversial points. Recent findings: Current evidence appears to suggest that resistin is a pro-inflammatory cytokine. Thus, like many other adipocytokines, resistin may possess a dual role in contributing to metabolic disease: first through its direct effects on substrate metabolism and second, through regulating inflammation within its target tissues. The chemistry of resistin has also been the subject of investigation and like adiponectin, the homo-oligomerization of this protein has a bearing on its function. Summary: The most recent advances include the identification of circulating higher molecular weight structures of resistin in both rodent and human serum. This has been complemented by work casting light on the function and purpose of multimeric resistin in mice. Resistin appears to have effects on substrate metabolism through impairment of insulin action, particularly in the liver, but in addition, also has effects on insulin independent pathways.

Original languageEnglish (US)
Pages (from-to)170-175
Number of pages6
JournalCurrent Opinion in Lipidology
Volume17
Issue number2
DOIs
StatePublished - Apr 1 2006

Fingerprint

Resistin
Adipokines
Metabolism
Insulin
Rodentia
Glucose
Adiponectin
Metabolic Diseases
Molecular Structure
Oligomerization
Type 2 Diabetes Mellitus
Cysteine
Insulin Resistance
Substrates
Medical problems
Homeostasis
Obesity
Molecular Weight
History
Liver

Keywords

  • Insulin resistance
  • Obesity
  • Resistin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Resistin. / McTernan, Philip G.; Kusminski, Christine M.; Kumar, Sudhesh.

In: Current Opinion in Lipidology, Vol. 17, No. 2, 01.04.2006, p. 170-175.

Research output: Contribution to journalReview article

McTernan, Philip G. ; Kusminski, Christine M. ; Kumar, Sudhesh. / Resistin. In: Current Opinion in Lipidology. 2006 ; Vol. 17, No. 2. pp. 170-175.
@article{8f416a84ae4a4036915c8834f0e39841,
title = "Resistin",
abstract = "Purpose of review: Resistin, a cysteine-rich 12.5 kDa polypeptide, is a recently discovered adipocytokine with a controversial history regarding its role in the pathogenesis of obesity-mediated insulin resistance and type 2 diabetes mellitus. Whilst current studies appear to re-affirm the role of resistin on glucose homeostasis in rodent systems, we are still unravelling the functionality of resistin in human biology in respect to glucose metabolism and insulin signalling. This review will summarize the current knowledge, put into context the developments to date and discuss the controversial points. Recent findings: Current evidence appears to suggest that resistin is a pro-inflammatory cytokine. Thus, like many other adipocytokines, resistin may possess a dual role in contributing to metabolic disease: first through its direct effects on substrate metabolism and second, through regulating inflammation within its target tissues. The chemistry of resistin has also been the subject of investigation and like adiponectin, the homo-oligomerization of this protein has a bearing on its function. Summary: The most recent advances include the identification of circulating higher molecular weight structures of resistin in both rodent and human serum. This has been complemented by work casting light on the function and purpose of multimeric resistin in mice. Resistin appears to have effects on substrate metabolism through impairment of insulin action, particularly in the liver, but in addition, also has effects on insulin independent pathways.",
keywords = "Insulin resistance, Obesity, Resistin, Type 2 diabetes",
author = "McTernan, {Philip G.} and Kusminski, {Christine M.} and Sudhesh Kumar",
year = "2006",
month = "4",
day = "1",
doi = "10.1097/01.mol.0000217899.59820.9a",
language = "English (US)",
volume = "17",
pages = "170--175",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Resistin

AU - McTernan, Philip G.

AU - Kusminski, Christine M.

AU - Kumar, Sudhesh

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Purpose of review: Resistin, a cysteine-rich 12.5 kDa polypeptide, is a recently discovered adipocytokine with a controversial history regarding its role in the pathogenesis of obesity-mediated insulin resistance and type 2 diabetes mellitus. Whilst current studies appear to re-affirm the role of resistin on glucose homeostasis in rodent systems, we are still unravelling the functionality of resistin in human biology in respect to glucose metabolism and insulin signalling. This review will summarize the current knowledge, put into context the developments to date and discuss the controversial points. Recent findings: Current evidence appears to suggest that resistin is a pro-inflammatory cytokine. Thus, like many other adipocytokines, resistin may possess a dual role in contributing to metabolic disease: first through its direct effects on substrate metabolism and second, through regulating inflammation within its target tissues. The chemistry of resistin has also been the subject of investigation and like adiponectin, the homo-oligomerization of this protein has a bearing on its function. Summary: The most recent advances include the identification of circulating higher molecular weight structures of resistin in both rodent and human serum. This has been complemented by work casting light on the function and purpose of multimeric resistin in mice. Resistin appears to have effects on substrate metabolism through impairment of insulin action, particularly in the liver, but in addition, also has effects on insulin independent pathways.

AB - Purpose of review: Resistin, a cysteine-rich 12.5 kDa polypeptide, is a recently discovered adipocytokine with a controversial history regarding its role in the pathogenesis of obesity-mediated insulin resistance and type 2 diabetes mellitus. Whilst current studies appear to re-affirm the role of resistin on glucose homeostasis in rodent systems, we are still unravelling the functionality of resistin in human biology in respect to glucose metabolism and insulin signalling. This review will summarize the current knowledge, put into context the developments to date and discuss the controversial points. Recent findings: Current evidence appears to suggest that resistin is a pro-inflammatory cytokine. Thus, like many other adipocytokines, resistin may possess a dual role in contributing to metabolic disease: first through its direct effects on substrate metabolism and second, through regulating inflammation within its target tissues. The chemistry of resistin has also been the subject of investigation and like adiponectin, the homo-oligomerization of this protein has a bearing on its function. Summary: The most recent advances include the identification of circulating higher molecular weight structures of resistin in both rodent and human serum. This has been complemented by work casting light on the function and purpose of multimeric resistin in mice. Resistin appears to have effects on substrate metabolism through impairment of insulin action, particularly in the liver, but in addition, also has effects on insulin independent pathways.

KW - Insulin resistance

KW - Obesity

KW - Resistin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33645510270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645510270&partnerID=8YFLogxK

U2 - 10.1097/01.mol.0000217899.59820.9a

DO - 10.1097/01.mol.0000217899.59820.9a

M3 - Review article

C2 - 16531754

AN - SCOPUS:33645510270

VL - 17

SP - 170

EP - 175

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 2

ER -